Keros Therapeutics(KROS) Newsfilter·2025-04-10 10:00Core Viewpoint - Keros Therapeutics, Inc. has initiated a formal review process to evaluate strategic alternatives aimed at maximizing stockholder value, including potential sale or business combination, continued investment in its pipeline, or returning excess capital to stockholders [1][2] Strategic Review Process - The Board of Directors has formed a Strategic Committee to oversee the review process, which will consider a comprehensive range of strategic alternatives [1] - There is no set deadline for the completion of the review process, and Keros plans to provide a preliminary update within 60 days of the announcement [2] Adoption of Stockholder Rights Plan - Keros has adopted a limited-duration stockholder rights plan to protect the integrity of the strategic review process, responding to significant stock accumulations by investors [3][4] - The rights plan aims to ensure fair participation in the review process and to prevent any entity from gaining control without paying an appropriate control premium [4] Rights Plan Details - The rights plan includes a dividend of one preferred share purchase right for each outstanding share of common stock, effective April 24, 2025, with rights becoming exercisable if ownership exceeds 10% [6] - Rights will allow holders to purchase additional shares at twice the market value if triggered, while existing stockholders at or above the threshold are grandfathered [6] - The rights will expire on April 9, 2026, unless redeemed or exchanged earlier by Keros [7] Company Overview - Keros Therapeutics is focused on developing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins, with product candidates targeting pulmonary arterial hypertension, neuromuscular diseases, and cytopenias [9]